CGEM – cullinan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? [Yahoo! Finance]
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Form 4 Cullinan Therapeutics, For: May 06 Filed by: Michaelson Jennifer
Form 144 Cullinan Therapeutics, Filed by: Michaelson Jennifer
Form 4 Cullinan Therapeutics, For: Apr 29 Filed by: Fenton Mary Kay
Form 3 Cullinan Therapeutics, For: Apr 29 Filed by: Fenton Mary Kay
Form 8-K Cullinan Therapeutics, For: Apr 29
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.